Loading stock data…
$56.69+0.09 (+0.16%)
Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States.
Disc Medicine, Inc. in the Healthcare sector is trading at $56.69 with a market capitalization of $3.0B. Wall Street consensus targets $103.17 (12 analysts), implying a +82.0% move over the next 12 months. The stock is currently 43% below its 52-week high of $99.50, remaining 20.0% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the safe zone. Risk note: RSI 20 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 75/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$65.08M↑ | -$69.52M↓ | -$66.97M↑ | -$67.70M↓ | -$61.41M |
| Net Income | -$59.53M↑ | -$63.50M↓ | -$60.53M↑ | -$62.32M↓ | -$55.25M |
Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United S...